Oruka Therapeutics Reports Q2 2026 Financial Results

What Happened

• On August 10, 2026, Oruka Therapeutics, Inc. announced its financial results for the second quarter ended June 30, 2026 and furnished a press release reporting those results as Exhibit 99.1 to an SEC Form 8-K (Item 2.02: Results of Operations and Financial Condition).

Key Details

• Press release announcing Q2 2026 results issued and furnished to the SEC on August 10, 2026 (Exhibit 99.1).
• Reporting period covered: quarter ended June 30, 2026 (Item 2.02).
• The Form 8-K also includes the Inline XBRL cover page data (Exhibit 104).

Why It Matters

• This filing is the company’s formal disclosure that its quarterly operating and financial results are available; investors should read the furnished press release for specific figures (revenue, expenses, cash position, guidance) and monitor the company’s upcoming 10-Q filing for complete financial statements and notes.
• No other material items (such as executive changes or mergers) were reported on this Form 8-K, so the primary takeaway is the availability of the Q2 results announcement.